Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Macular Edema Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Macular Edema Overview | 8 | 1 |
| Macular Edema Therapeutics under Development by Companies | 9 | 1 |
| Macular Edema Pipeline Products Glance | 10 | 3 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Macular Edema Products under Development by Companies | 13 | 1 |
| Macular Edema Companies Involved in Therapeutics Development | 14 | 12 |
| ActiveSite Pharmaceuticals, Inc. | 14 | 1 |
| Ampio Pharmaceuticals, Inc. | 15 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 16 | 1 |
| Clearside BioMedical, Inc. | 17 | 1 |
| Coherus BioSciences, Inc. | 18 | 1 |
| Mabion SA | 19 | 1 |
| Pfizer Inc. | 20 | 1 |
| Precision Ocular Ltd | 21 | 1 |
| Promedior, Inc. | 22 | 1 |
| Taiwan Liposome Company, Ltd. | 23 | 1 |
| Valeant Pharmaceuticals International, Inc. | 24 | 1 |
| Xbrane Biopharma AB | 25 | 1 |
| Macular Edema Therapeutics Assessment | 26 | 10 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Combination Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 20 |
| (aflibercept + triamcinolone acetonide) Drug Profile | 36 | 3 |
| ACX-107 Drug Profile | 39 | 1 |
| ASPPDC-020 Drug Profile | 40 | 1 |
| BLO-021 Drug Profile | 41 | 1 |
| celecoxib Drug Profile | 42 | 3 |
| danazol Drug Profile | 45 | 4 |
| dexamethasone sodium phosphate SR Drug Profile | 49 | 1 |
| HO-10 Drug Profile | 50 | 1 |
| PRM-167 Drug Profile | 51 | 1 |
| ranibizumab biosimilar Drug Profile | 52 | 1 |
| ranibizumab biosimilar Drug Profile | 53 | 1 |
| ranibizumab biosimilar Drug Profile | 54 | 1 |
| ranibizumab biosimilar Drug Profile | 55 | 1 |
| Macular Edema Dormant Projects | 56 | 1 |
| Macular Edema Discontinued Products | 57 | 1 |
| Macular Edema Product Development Milestones | 58 | 4 |
| Featured News &Press Releases | 58 | 1 |
| Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting | 58 | 1 |
| Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion | 58 | 1 |
| Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | 59 | 1 |
| Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration | 60 | 1 |
| Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion | 60 | 2 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |
